CXCR4 Expression in Bladder Transitional Cell Carcinoma and Its Relationship with Clinicopathological Features

被引:8
作者
Li, Yangle [1 ]
Chen, Minfeng [1 ]
Yuan, Junbin [1 ]
Zhou, Xu [1 ]
He, Wei [1 ]
Zu, Xiongbing [1 ]
Qi, Lin [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Hunan, Peoples R China
关键词
Bladder transitional cell carcinoma; CXCR4; Lymph node metastasis; Prognosis; CHEMOKINE RECEPTOR CXCR4; CANCER; METASTASIS; INVASION;
D O I
10.1159/000351952
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To elucidate the role of CXCR4 in the metastasis of bladder transitional cell carcinoma (BTCC) by examining CXCR4 expression in BTCC tissue and its correlation with clinicopathological features. Methods: The expression of CXCR4 was assessed in bladder tissues from 70 BTCC patients and 18 normal controls, respectively, using immunohistochemistry. The correlation of CXCR4 expression with lymph node metastasis was also examined by determining the lymphatic vessel density (LVD). Results: Overexpression of CXCR4 was detected in 58/70(82.9%) BTCC tissues, whereas only in 3/18 (16.7%) normal bladder tissues. The expression was significantly higher in BTCC than that in normal controls (p <0.01). CXCR4 expression level was closely associated with tumor size, pathological grades, clinical stages, and pelvic lymph node metastasis (p < 0.05). Multivariate analysis indicated that CXCR4 expression and lymph node metastasis were independent predictors for disease-free survival (both p <0.05). The disease-free survival rate among the patients with high CXCR4 expression level was remarkably lower than that among the patients with no or low level expression (p < 0.01). Conclusion: Highly expressed in BTCC tissues, CXCR4 may play a critical role in the metastasis of BTCC, and the expression level in biopsy specimens might be a good indicator of lymph node metastasis. Copyright 2013 S. Karger AG, Basel
引用
收藏
页码:157 / 163
页数:7
相关论文
共 23 条
  • [1] Bachelder RE, 2002, CANCER RES, V62, P7203
  • [2] The significance of cancer cell expression of the chemokine receptor CXCR4
    Balkwill, F
    [J]. SEMINARS IN CANCER BIOLOGY, 2004, 14 (03) : 171 - 179
  • [3] Chemokine biology in cancer
    Balkwill, F
    [J]. SEMINARS IN IMMUNOLOGY, 2003, 15 (01) : 49 - 55
  • [4] Computerized Tomography for Detecting Perivesical Infiltration and Lymph Node Metastasis in Invasive Bladder Carcinoma
    Baltaci, Sumer
    Resorlu, Berkan
    Yagci, Cemil
    Turkolmez, Kadir
    Gogus, Cagatay
    Beduk, Yasar
    [J]. UROLOGIA INTERNATIONALIS, 2008, 81 (04) : 399 - 402
  • [5] Expression analysis and potential functional role of the CXCR4 chernokine receptor in bladder cancer
    Eisenhardt, A
    Frey, U
    Tack, M
    Rosskopf, D
    Lümmen, G
    Rübben, H
    Siffert, W
    [J]. EUROPEAN UROLOGY, 2005, 47 (01) : 111 - 117
  • [6] HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor
    Feng, Yu
    Broder, Christopher C.
    Kennedy, Paul E.
    Berger, Edward A.
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (11) : 872 - 877
  • [7] A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma
    Geminder, H
    Sagi-Assif, O
    Goldberg, L
    Meshel, T
    Rechavi, G
    Witz, IP
    Ben-Baruch, A
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (08) : 4747 - 4757
  • [8] Chemokines:: Agents for the immunotherapy of cancer?
    Homey, B
    Müller, A
    Zlotnik, A
    [J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (03) : 175 - 184
  • [9] Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes
    Kitadai, Y
    Kodama, M
    Cho, SD
    Kuroda, T
    Ochiumi, T
    Kimura, S
    Tanaka, S
    Matsumura, S
    Yasui, W
    Chayama, K
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (03) : 388 - 392
  • [10] Bladder cancer clinical trials
    Lerner, SP
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (04) : 275 - 279